Fibrous dysplasia is a benign developmental anomaly of bone, often affecting craniofacial bones. We report on a 9-year-old boy, who presented for routine checkup. Clinical examination revealed unilateral exophthalmos of his left eye without decrease of visual acuity or double vision. Radiologic studies showed characteristic extensive changes of fibrous dysplasia involving the left frontal bone, left orbital bones, maxillary and sphenoid bones. The patient was started on conservative therapy and the condition of the affected eye remained stable. As fibrous dysplasia of the orbital bones can be a cause of significant dysfunction and a treatable cause of blindness, early diagnosis is very important. These patients are most likely to present with complaints of facial asymmetry, including axial, vertical, or horizontal displacement of the globe, or visual loss. Therefore the ophthalmologist plays an important role in the early diagnosis of fibrous dysplasia.

Keywords:
Exophthalmos, Fibrous dysplasia, Orbital compression
1.
Bullock JD, Goldberg SH, Rakes SM: Orbital tumors in children. Ophthal Plast Reconstr Surg 1989;5:13–16.
2.
Shields JA, Bakewell B, Augsburger JJ, et al: Classification and incidence of space-occupying lesions of the orbit: A survey of 645 biopsies. Arch Ophthalmol 1984;102:1606–1611.
3.
Reed RJ: Fibrous dysplasia of bone. Arch Pathol 1963;75:480–495.
4.
Chapurlat RD, Delmas PD, Liens D, et al: Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 1997;12:1746–1752.
5.
Liens D, Delmas PD, Meunier PJ: Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994;343:953–954.
6.
Mortensen A, Bojsen-Moller M, Rasmussen P: Fibrous dysplasia of the skull with acromegaly and sarcomatous transformation: Two cases with a review of the literature. J Neurooncol 1989;7:25–29.
7.
Kransdorf MJ, Moser RP Jr, Gilkey FW: Fibrous dysplasia. Radiographics 1990;10:519–537.
8.
Katz BJ, Nerad JA: Ophthalmic manifestations of fibrous dysplasia: A disease of children and adults. Ophthalmology 1998;105:2207–2215.
9.
Bibby K, McFadzean R: Fibrous dysplasia of the orbit. Br J Ophthalmol 1994;78:266–270.
10.
Moore AT, Buncic JR, Munro IR: Fibrous dysplasia of the orbit in childhood: Clinical features and management. Ophthalmology 1985;92:12–20.
11.
Rootman J, Kemp E, Lapointe JS: Orbital tumors originating in bone; in Rootman J (ed): Diseases of the Orbit: A Multidisciplinary Approach. Philadelphia, Lippincott, 1988, pp 354–379.
12.
MacDonald-Jankowsi DS: Fibro-osseous lesions of the face and jaws. Clin Radiol 2004;59:11–25.
13.
Lichtenstein L, Jaffe H: Fibrous dysplasia of bone: A condition affecting one, several, or many bones, the graver cases of which may represent abnormal pigmentation, premature sexual development, hyperthyroidism, or still other extraskeletal abnormalities. Arch Pathol 1942;33:777–816.
14.
Schlumberger HG: Fibrous dysplasia of single bones (monostotic fibrous dysplasia). Mil Surg 1947;99:504–527.
15.
Heller AJ, DiNardo LJ, Massey D: Fibrous dysplasia, chondrosarcoma, and McCune-Albright syndrome. Am J Otolaryngol 2001;22:297–301.
16.
Coley BL, Stewart FW: Bone sarcoma in polyostotic fibrous dysplasia. Ann Surg 1945;121:872–881.
17.
Schwartz DT, Alpert M: The malignant transformation of fibrous dysplasia. Am J Med Sci 1964;247:1–20.
18.
Osguthorpe JD, Gudeman SK: Orbital complications of fibrous dysplasia. Otolaryngol Head Neck Surg 1987;97:403–405.
19.
Weisman JS, Hepler RS, Vinters HV: Reversible visual loss caused by fibrous dysplasia. Am J Ophthalmol 1990;110:244–249.
20.
Tyl JW, Blank LE, Koorneef L: Brachytherapy in orbital tumors. Ophthalmology 1997;104:1475–1479.
21.
Goldberg RA, Rootman J: Clinical characteristics of metastatic orbital tumors. Ophthalmology 1990;97:620–624.
22.
Edelstein C, Goldberg RA, Rubino G: Unilateral blindness after ipsilateral prophylactic transcranial optic canal decompression for fibrous dysplasia. Am J Ophthalmol 1998;126:469–471.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.